DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Nisa Investment Advisors LLC (2024)

Nisa Investment Advisors LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 15.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,460 shares of the medical device company's stock after acquiring an additional 9,092 shares during the period. Nisa Investment Advisors LLC's holdings in DexCom were worth $7,762,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. DSM Capital Partners LLC bought a new stake in shares of DexCom in the 4th quarter valued at about $28,000. Crewe Advisors LLC bought a new stake in shares of DexCom during the 1st quarter worth $29,000. Riverview Trust Co purchased a new stake in shares of DexCom during the 1st quarter worth approximately $32,000. Smithfield Trust Co increased its position in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company's stock worth $40,000 after buying an additional 165 shares during the last quarter. Finally, Sound Income Strategies LLC grew its stake in shares of DexCom by 41.7% during the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company's stock worth $47,000 after acquiring an additional 100 shares during the period. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of the business's stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of the business's stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The disclosure for this sale can be found here. Insiders have sold a total of 4,135 shares of company stock worth $446,797 over the last ninety days. Corporate insiders own 0.30% of the company's stock.

DexCom Trading Up 4.1 %

Shares of NASDAQ:DXCM traded up $3.04 during mid-day trading on Monday, hitting $77.69. The stock had a trading volume of 3,618,697 shares, compared to its average volume of 3,756,353. The company has a market cap of $30.90 billion, a PE ratio of 50.12, a P/E/G ratio of 2.18 and a beta of 1.16. The company's 50 day moving average is $98.89 and its 200-day moving average is $117.69. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company's revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.34 EPS. On average, sell-side analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research reports. Stifel Nicolaus decreased their price objective on DexCom from $132.00 to $90.00 and set a "buy" rating on the stock in a report on Friday, July 26th. JPMorgan Chase & Co. lowered DexCom from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. Wells Fargo & Company reduced their target price on shares of DexCom from $145.00 to $80.00 and set an "overweight" rating on the stock in a research report on Friday, July 26th. BTIG Research lowered their price objective on DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a research note on Friday, July 26th. Finally, Piper Sandler reduced their price target on shares of DexCom from $150.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $111.63.

View Our Latest Stock Analysis on DXCM

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

• Five stocks we like better than DexCom
• REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today
• Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
• High Flyers: 3 Natural Gas Stocks for March 2022
• 2 Option Strategies to Maximize Profits in a Bear Market
• Which Wall Street Analysts are the Most Accurate?
• Lululemon Stock Gears Up for a Massive Comeback Rally

Should you invest $1,000 in DexCom right now?

Before you consider DexCom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.

While DexCom currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here